A randomized, double-blind, placebo-controlled, single- and multiple-dose phase 1 study of VE202, a defined bacterial consortium for treatment of inflammatory bowel disease: safety and colonization dynamics of a novel live biotherapeutic product in h
VE202 was well tolerated. Following antibiotic pretreatment, rapid and durable gut colonization of VE202 strains was observed, most significantly in participants administered multiple doses (NCT03931447).
Authors
- Ling‐Yang Hao
- Bernat Olle (ORCID: https://orcid.org/0000-0003-2220-703X)
- Melissa Marko
- Emily Crossette (ORCID: https://orcid.org/0000-0003-3645-2909)
- Rose L. Szabady (ORCID: https://orcid.org/0000-0002-1281-7064)
- Anna Yuan (ORCID: https://orcid.org/0000-0001-5619-5175)
- Rajita Menon (ORCID: https://orcid.org/0000-0002-4767-0971)
- Jeffrey L. Silber (ORCID: https://orcid.org/0009-0008-9834-2071)
- Sunita Bhagat (ORCID: https://orcid.org/0000-0002-7597-1085)
- Esi Lamousé‐Smith (ORCID: https://orcid.org/0000-0002-1067-5795)
- Tokuwa Kanno (ORCID: https://orcid.org/0000-0002-1275-7911)
- Jason M. Norman (ORCID: https://orcid.org/0000-0001-5049-8415)
- Lynn Tomsho
Institutions
- Janssen (United States) (US)
- Vedantra Pharmaceuticals (United States) (US)
Publication Details
- Journal
- European Journal of Gastroenterology & Hepatology
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1097/meg.0000000000003098
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 0.00